trial summary · NCT07556484
Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
Pharmacokinetics Of Emulsified Avacopan In ANCA-associated Vasculitis With Severe Diffuse Alveolar Hemorrhage
Trial record from the TrialBase DB dataset, status RECRUITING, condition Diffuse Alveolar Hemorrhage, sponsored by Mayo Clinic. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to determine the 72-hour pharmacokinetics of emulsified avacopan at a dose of 30 mg twice daily given to up to 6 patients with active severe GPA or MPA with diffuse alveolar hemorrhage (DAH) requiring mechanical ventilation for respiratory support.
Source record: https://clinicaltrials.gov/study/NCT07556484
Facts
| registry id | NCT07556484 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Diffuse Alveolar Hemorrhage |
| sponsor | Mayo Clinic |
| sponsor class | OTHER |
| enrollment | 6 |
| start date | 2027-08-01 |
| primary completion | 2028-08-01 |
| completion | 2028-08-01 |
| results posted | not reported |
Conditions
- Diffuse Alveolar Hemorrhage
- Antineutrophil Cytoplasmic Antibody Positive Vasculitis
Interventions
- Avacopan
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.